Nebido (Testosterone Undecanoate)

Testosterone undecanoate, the active ingredient in Nebido, is an androgen presented as an injectable solution for intramuscular administration. It is used in hormone replacement therapy to correct testosterone deficiency and treat male hypogonadism in adult patients.

GNH USA supplies Nebido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for hormone therapy programs. Our distribution network ensures compliance with local regulations and maintains product integrity throughout the supply chain. We work with qualified logistics partners to guarantee timely delivery and appropriate temperature control where required.

Nebido (testosterone undecanoate) is used in androgen replacement therapy to restore normal testosterone levels. - Male hypogonadism: restores physiological testosterone concentrations, improving sexual function, mood and muscle mass. - Testosterone deficiency: alleviates symptoms such as fatigue, loss of libido and reduced bone density. - Delayed puberty in males: supports development of secondary sexual characteristics when endogenous production is insufficient.

Nebido may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Headache: transient headache. - Acne: increased sebaceous gland activity leading to acne. - Fluid retention: mild edema or weight gain.

Serious or Rare Side Effects: - Polycythemia: elevated red blood cell count that may increase thrombotic risk. - Cardiovascular events: rare occurrences of myocardial infarction or stroke. - Liver toxicity: abnormal liver function tests or hepatitis.

Before prescribing Nebido, clinicians should evaluate several safety considerations to minimise risks. - Cardiovascular assessment: review history of heart disease, hypertension or thromboembolic events. - Hematocrit monitoring: check red blood cell levels periodically to detect polycythemia. - Prostate evaluation: assess for benign prostatic hyperplasia or prostate cancer before initiating therapy. - Lipid profile: monitor cholesterol and triglycerides as androgen therapy may affect lipid metabolism. - Fertility counseling: discuss potential suppression of spermatogenesis with patients desiring future fertility. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nebido can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid): - Anticoagulants: increased risk of thrombosis due to polycythemia. - CYP3A4 inhibitors: may raise testosterone levels, enhancing androgenic effects. - Glucocorticoids: can exacerbate fluid retention and hypertension.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemics: testosterone may affect glucose control. - Antihypertensives: possible reduction in blood pressure efficacy. - Lipid‑lowering agents: monitor lipid profile as changes may occur.